Skip to content

Platform
- Overview
- Publications
Pipeline
Patients
About Us
Partnerships
News
Careers

Platform
- Overview
- Publications
Pipeline
Patients
About Us
Partnerships
News
Careers

BioPharma Dive: Cour gets $105M, pharma help to ‘reprogram’ autoimmune disease

By lsc-webmaster / January 30, 2024

COUR Pharmaceuticals Appoints Dannielle Appelhans as Chief Operating Officer

Crain’s Chicago Business: Venture capital, Big Pharma put $105M into Cour Pharmaceuticals’ immunology therapies

Skokie, Illinois
info@courpharma.com

Science

Platform
Publications
Pipeline

Patients

Overview
Patient Resources
CNP-103 Clinical Trial in Type 1 Diabetes
CNP-106 Clinical Trial in Myasthenia Gravis

Company

About Us
Partnerships
News
Careers

Privacy Policy
Terms of use
Accessibility
Expanded Access Policy
Cookie policy

© 2025 COUR Pharmaceuticals

Scroll to Top